NM_000077.5:c.178G>C
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PM5PP3_Strong
The NM_000077.5(CDKN2A):c.178G>C(p.Ala60Pro) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A60V) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000077.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CDKN2A | ENST00000304494.10 | c.178G>C | p.Ala60Pro | missense_variant | Exon 2 of 3 | 1 | NM_000077.5 | ENSP00000307101.5 | ||
CDKN2A | ENST00000579755.2 | c.221G>C | p.Gly74Ala | missense_variant | Exon 2 of 3 | 1 | NM_058195.4 | ENSP00000462950.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial melanoma Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this missense change in CDKN2A (p16INK4a) is likely to be disruptive. These same algorithms do not agree on the potential impact of this variant in the CDKN2A (p14ARF) protein (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with proline at codon 60 of the CDKN2A (p16INK4a) protein (p.Ala60Pro). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and proline. Alternatively, this sequence change replaces glycine with alanine at codon 74 of the CDKN2A (p14ARF) protein (p.Gly74Ala). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and alanine. The CDKN2A gene encodes two different proteins, p16INK4a and p14ARF, which are translated from alternative transcripts that have different open reading frames. A different variant (c.178_179delinsCG) giving rise to a different protein effect in CDKN2A (p16INK4a) (p.Ala60Arg) but the same protein effect seen here in CDKN2a (p14ARF) (p.Gly74Ala), has been reported in the literature in a single single family affected with melanoma (PMID: 19260062). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at